Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06583291
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-01
Brief Title:
iDAP Injection in the Treatment of Parkinsons Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single Center Open-label Study to Evaluate the Safety Tolerability and Preliminary Efficacy of Allogeneic Dopaminergic Neural Precursor CelliDAP Injection in the Treatment of Parkinsons Disease
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to evaluate the safety tolerability and preliminary efficacy that iDAP has on Parkinsons disease PD patients
Detailed Description:
Parkinsons disease PD is a common neurodegenerative disease in the middle-aged and elderly It is the third killer of the middle-aged and elderly after tumors and cardiovascular and cerebrovascular diseases Its main clinical manifestations are resting tremor reduced voluntary movement muscle rigidity postural reflex impairment and autonomic dysfunction which seriously affect patients work ability and quality of life It is estimated that nearly 100000 people in China become new Parkinsons patients every year Experts from the World Health Organization predict that the number of Parkinsons patients in China will reach 5 million in 2030 which will be more than half of the worlds total As the disease progresses the symptoms of Parkinsons patients will become increasingly severe The high prevalence and high disability rate of Parkinsons disease bring heavy burdens to individuals families and society
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None